Open in app

U.S. Food and Drug Administration Approves VUITY – The First Eye Drop to Treat Presbyopia

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:

VUITYTM (pilocarpine HCl ophthalmic solution) 1.25 percent has been approved by the US Food and Drug Administration (FDA) for the treatment of presbyopia, also known as age-related hazy near vision in adults. VUITYTM is the first and only FDA-approved eye drop to treat this prevalent and degenerative eye disease, which affects 128 million Americans, or over half of the adult population in the United States. VUITYTM is an improved formulation of pilocarpine, an established eye care treatment, given using pHastTM technology, and is specifically intended for presbyopia. This drop can be given by putting one drop into each eye once a day. It improves close and intermediate vision without affecting distant vision in as little as 15 minutes and lasts up to 6 hours.

(Picture:- Eyehealthnepal)

VUITYTM was approved by the FDA based on the results of two pivotal phase 3 clinical studies, GEMINI 1 and GEMINI 2, which assessed the efficacy, safety, and tolerability of VUITYTM in the treatment of presbyopia. Headache, eye redness, conjunctival hyperaemia, and uncommon retinal detachment were the most prevalent adverse effects, each occurring at a rate of > 5%. VUITY is a prescription eyedrop used to cure presbyopia.